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  1 1.  Introduction 
  Price indexes provide a way to summarize changes in prices of individual goods 
and services using an aggregate statistic.  An important use of these indexes is to 
decompose changes in spending into price and quantity components.  This is the role that 
price indexes play in the National Income and Product Accounts to obtain measures of 
real output and productivity.  Price indexes are also used in the National Health 
Expenditure Accounts to provide information on the drivers of spending growth in the 
nation’s health care sector.  More broadly, health economists have used similar 
decompositions to inform policy debates about which levers may be used to contain cost 
growth (Merlis 2000).   
 Numerically,  most  price  indexes can be expressed as functions of weighted 
averages of price change; many of the measurement issues discussed in the literature 
relate to which particular formula and weights is most appropriate in constructing the 
index.
1  There has been significant research into these issues and, indeed, the Bureau of 
Labor Statistics’ official statistics have undergone substantial improvements in recent 
decades owing to research that pointed to deficiencies in existing indexes and provided 
new methods to improve those measures.   
Beyond weighting issues, there is the problem that some price changes are 
accompanied by changes in the quality of goods.  Ideally, one would like a “constant-
quality price index” that would allocate improvements in goods as an increase in quantity 
consumed, not price paid.  Because goods are typically multifaceted and have many 
attributes that are valued by consumers, the measurement of “quality” is typically 
summarized using consumers’ valuations of the attributes of the goods.  For many goods 
(like computers), these valuations are inferred from the prices that consumers pay for 
them.  For medical care, it is widely understood that the prices patients pay for goods and 
services will typically not reflect how much they value them.  This presents a major 
obstacle in measuring changes in the quality of medical care using techniques that have 
been applied successfully in other industries.    
Related to these difficulties in valuing quality change is the broader problem that 
price indexes for medical care do not have a clear link to patients’ welfare.  This is 
because those inferences usually rely on a cost of living index (COLI) interpretation for 
                                                 
1 See Schultze and Mackie (2002) for a recent review of the issues 
  2the indexes.  The nature of health-related decisions is such that this interpretation is 
strained, at best, for those transactions:  Doctors play a key role in prescribing medical 
care—raising potential principal agent issues—and most patients use health insurance to 
cover at least part of their payments for medical services—raising moral hazard issues.  
Finally, the simple static utility maximization paradigm underlying COLI theory does not 
align well with how decisions for medical care are actually made.
2    
We therefore focus on the measurement issues, how the indexes are constructed, 
and how they may be used to decompose the growth in spending into price and quantity 
components.  We do this for one of the major inputs in the provision of medical care: 
prescription drugs.  While one ultimately wants to measure the output of the health sector 
as the marginal improvement to health status from all goods and services (Abraham and 
Mackie 2005), there are nonetheless important uses of price indexes for the individual 
inputs, such as measuring productivity growth for the drug industry and parsing out the 
drivers of growth in spending.  
The chapter is organized as follows.  We begin with a discussion of two 
definitional issues that turn out to be numerically important.  Section 3 discusses the 
relative merits of different aggregation methods as they relate to the drug industry.  A 
review of what is known about the issue of quality change is given in Section 4 and 
Section 5 concludes with a summary of the issues.     
2.  Definitional Issues 
  We begin with a discussion of how the “product” provided by the drug industry 
should be defined and how quantity and price should be measured.  The particular price 
that one pays for a drug depends importantly on the attributes of the drug:  for example, 
active ingredient (sometimes called the “molecule”), strength (e.g. 25mg), and dosage 
form (e.g. tablet).  Which of these attributes define the “product?”  Another issue that 
turns out to matter is how one defines the unit of quantity and, hence, the price (for 
example, should it be price per day or price per prescription?).    
Defining the product: Drug vs. Molecure 
                                                 
2 See Cutler et. al. (1998) for an alternative paradigm that better takes into account the dynamic nature of 
medical care and the role of insurance payments.      
  3How one defines the “product” or “output” provided by the drug industry has 
important implications for how changes in spending are split out into price versus 
quantity components.   
An important issue in this regard is how price indexes should handle the entry of 
generic drugs:  should branded and generic versions of the same drug be considered the 
same or separate drugs?  One landmark contribution of this literature was the 
demonstration that this distinction is numerically important for several prominent 
medications:  Berndt, Cockburn and Griliches (1996) for antidepressants and Griliches 
and Cockburn (1994) for antibiotics.  
  For price index purposes, one wants to define a homogeneous product, so that 
tracking its price over time does not reflect any changes in the good’s attributes.  The 
issue is very similar to the problem of defining the market in antitrust cases:  should the 
market be defined as aluminum foil or as all wrapping materials—foil, wax paper, saran 
wrap, etc.  The key issue is how substitutable consumers find these goods.   
There are two commonly used product definitions for drugs.  One approach is to 
use the NDC code (National Drug Code, a 10-digit code that gives information on the 
attributes of the drug).  An example of the level of granularity is a prescription for 
Lipitor, 20mg, 30 tablets (NDC 0071-0156-23).  An alternate definition treats drugs with 
the same active ingredient as identical goods:  this uses the GPI code (Generic Product 
Identifier, a 14-digit code that contains 7 pairs of digits) to identify drugs that use the 
same active ingredient and strength.  For Lipitor, atorvastatin is the active ingredient and 
GPI 39400010100320 is the GPI code for the 20mg version of this drug.  Once generic 
versions enter the market, the 20mg versions of atorvastatin will share this GPI code with 
the branded version, Lipitor.  By contrast, a generic drug would not share Lipitor’s NDC 
code, but would have a unique code of its own.     
The important distinction between the NDC and GPI definitions lies in their 
treatment of generic goods.  Why does it matter?  Consider a simple example where a 
branded antidepressant sells for $1 a day and its price stays constant.  At some point, the 
branded drug loses patent protection and a generic version is introduced at 70 cents per 
day, with its price also remaining constant.  As patients switch to the less-expensive 
generic drug, overall revenues received by the drug industry fall.  Because price indexes 
are typically some function of weighted averages of price change, a price index that 
  4considers the two drugs as separate products (i.e., using the NDC definition) will show no 
price change because prices of the individual drugs did not change.  This means that the 
reduction in revenues will be attributed to a drop in quantities, even if the number of 
patients or prescriptions did not change.  At the other extreme, one can define the 
branded and generic versions as the same product (i.e., use of the GPI definition) and 
define the price as the average revenue per day of prescription, for example.  With this 
definition, the decline in revenues will translate into a decline in the average revenue, or 




The substitutability between the branded and generic versions of a drug is the key 
issue.  To the extent that patients only care about the active ingredient, the GPI definition, 
using the molecule definition, is the correct one.  One caveat, however, is that the inert 
ingredients are often different for branded and generic drugs.  As these inert ingredients 
often involve different side effects, many patients may well view the branded and generic 
versions of a drug as different goods and the GPI definition would not be appropriate.   
We illustrate the numerical importance of this issue using a dataset containing 
drug claims submitted to 12 HMO plans from 2003:1-2005:4.  The data are from 
Pharmetrics and are described in more detail in Aizcorbe and Nestoriak (2008).  We use 
200 million claims for oral medications that were purchased at retail pharmacies by 
patients covered by these HMOs.   
In our data, prices for generic drugs are, on average, 30% lower than the prices of 
their branded counterparts, suggesting that how one handles switches from branded to 
generic drugs could be numerically important.  (We obtained this estimate from a 
regression using data from 2003 that explained 82% of the variation in NDC prices using 
dummy variables for the molecule, strength, dosage form, manufacturer, type of health 
insurance plan, and branded versus generic status of the drug.) 
Following the literature, we constructed price indexes that represent the two 
extremes, one based on the NDC definition and the other on the GPI definition.  We 
found that the NDC-based price indexes grew about twice as fast as the molecule-based 
index:  2.6 versus 1.2 compound annual growth rates (CAGR) over 2003:1 to 2005:4.  
  5This difference is large, and reflects the influx of generics into the market over this 
period.  In our sample, the number of prescriptions filled for generic drugs grew from 
about 58% of all oral prescriptions in 2003 to over 60% in 2005.          
[TABLE 1] 
Exercises like this that compare the two extremes demonstrate the potential 
importance of the issue.  The literature has provided some methods for better folding 
generics into price indexes but some problems still remain.  The methods that have been 
proposed thus far tend to rely on consumer optimization problems and COLI theory:  
Fisher and Griliches (1995) and Griliches and Cockburn (1995) rely on estimates of 
reservation prices to fold in the new generic goods and Feenstra (1994) uses estimates of 
elasticities of substitution in an exact price index.  Even if these methods could, in 
principle, provide suitable first-order approximations to the problem, subsequent studies 
that attempted to implement these methods had difficulties:      
…. the use of econometric methods in constructing price indexes that incorporate 
the effects of new goods requires considerably more experimentation, perhaps 
with other data sets and families of products, and with specifications that include 
non-price factors affecting demand functions. .. .Future research should focus on 
the conditions under which the Feenstra, the Griliches and Cockburn or some 
other method is more likely to yield robust and plausible findings. (P. 263, 
Berndt, Kyle, and Ling 2003).  
 
For now, we note that price indexes defined on a GPI basis are likely to show 
slower price growth than those defined on an NDC basis.  Because the sensitivity of price 
indexes to different definitions often depends on whether the good is defined on an NDC 
or GPI basis, we will report both sets of indexes in this discussion.   
    
Defining units of “quantity”   
  How one defines the unit of measurement also has empirical implications for 
price measurement.  Among the definitions for price that are typically used are 1) price 
per day of treatment, 2) price per prescription, and 3) price per package.  The choice of 
definition is often influenced by the available data.  Price per day of treatment is a widely 
used definition, used both in studies of cost decompositions and hedonic studies, but 
  6requires information on the number of days of treatment associated with each 
prescription, as found in claims data.  Price per prescription is the basis for some IMS 
statistics (e.g., IMS National Prescription Audit); it also underlies the Consumer Price 
Index for prescription drugs and has been used in various decomposition studies.  Of 
these two, health economists typically view the price per day as the superior choice 
(Crown, Ling and Berndt 2002) because price per prescription confounds changes in 
utilization and price (increases in the number of days per prescription are represented as 
an increase in price per prescription, for example).    
Finally, other IMS data are reported at the “pack” level (e.g., a particular 
container with a specified number of tablets sold to pharmacies) and this price per 
package has also been used to represent price (e.g., IMS National Sales Perspectives, 
which tracks sales from wholesalers to pharmacies and other outlets).  This is the 
definition underlying the Producer Price Index for drugs and the price index used in the 
pharmaceutical components of the Federal Reserve Board’s Industrial Production Index.  
Because tracking the price of each package holds constant the number of medications 
(e.g., tablets) in the container, tracking changes in the price per package is tantamount to 
tracking changes in the “price per tablet.”   
Our data allow us to construct the three measures and compare them.  For this 
comparison, we use only claims where all three pieces of information are available.  
Consistent with the discussion in Merlis (2000), price indexes based on price per day tend 
to show slower price growth than those based on price per prescription.  This holds true 
regardless of which formula is used (Fisher price index or Laspeyres) or which product 
definition (NDC or GPI).  In our sample, the differences are large:  using the NDC 
definition, indexes based on price per prescription grow nearly twice as fast as those 
based on price per day; the differences are even larger using the GPI definition.  Indexes 
based on price per package also grow faster than the preferred price per day definition, 
but the differences are less pronounced.   
 
[TABLE 2]   
 
It is troublesome that changing the units of measurement can have such an impact 
on measured price growth.  To the extent that price per day of treatment is the preferred 
  7definition, it is also unfortunate that the necessary data to measure it this way are not as 
readily available as data on number of prescription or packages sold.     
 
3.  Aggregation Issues  
Once the product and unit of measurement are defined, one needs a formula to 
aggregate price changes across the individual products to obtain an aggregate statistic.  
The best practice method is to construct chained Fisher price indexes.  The Fisher 
formula is a superlative index number formula that has been shown to be superior to 
other aggregation formulas (Diewert 1992).  As discussed below, “chaining” indexes 
provides a way to bring new goods into the indexes more rapidly and, thus, more closely 
track the composition of goods sold in the market.  We also discuss the Laspeyres index, 
as it is often used in official price indexes and cost decompositions.   
Price Indexes 
  Price indexes provide a way to measure aggregate price change over some period 
by comparing the cost of purchasing a market basket at different points in time.  The 




0,1= [Σi Pi,1 Qi,0/ Σi Pi,0 Qi,0 ]             (1) 
 
where 0 and 1 denote two periods in time, a base and current period, respectively, and i 
indexes goods that are sold in both periods.  The Laspeyres tracks the cost of buying the 
Qi,0 basket at period 0 prices with the cost of buying it at period 1 prices.  The index can 




0,1 =   Σi wi,0
  Pi,1 / Pi , 0        (2) 
 
where the weights, wi,0, are the base period expenditure shares and the price relatives, Pi,1 
/ Pi,0 measure the price changes for individual drugs.  The weights, or shares, are often 
called “relative importances” and have been the focus of much of the work in the 
literature.  Written this way, it is easy to see that products in the base period market 
basket are only included in the index if they are sold in both periods (i.e., if one observes 
both Pi,0  and Pi,1 ).  That is, the index does not include price change for new goods—
  8goods that entered the market between the two periods—or for goods that exited the 
market after the base period.  Moreover, for goods that were sold in both periods, the 
Laspeyres fixes the relative importance of these goods at the base period levels and 
therefore does not reflect any changes in the composition of goods sold over time. 
  A Fisher Ideal index provides relative importances that are more closely aligned 




0,1  = { [Σi Pi,1 Qi,0/ Σi Pi,0 Qi,0 ] [Σi Pi,1 Qi,1/Σi Pi,0 Qi,1 ]  } 
1/2       (3)  
 
It is an average (a geometric average) of the Laspeyres index—the first term—and the 
Paasche index—the second term.
3  The Paasche index is similar to the Laspeyres except 
that it uses a different market basket to measure price change—it compares the actual 
cost of buying the bundle in period 1 (Σi Pi,1 Qi,1) to what it would have cost to buy that 
bundle at period 0 prices (Σi Pi,0 Qi,0).       




0,1  = { Σi wi,0
  Pi,1  / Pi,0 ] /  [Σi wi,0
  Pi,0 / Pi,1]  } 
1/2          (4) 
 
with the Laspeyres in the numerator and the inverse of a Paasche in the denominator.  
Here it is easy to see that, unlike the Laspeyres, the Fisher uses expenditure shares from 
both periods. So, as market shares change over time, the Fisher places a higher weight on 
goods that are gaining market share whereas the Laspeyres does not.   
Just like the Laspeyres, however, this index ignores the entry of new goods and 
the exit of older goods.  In a dynamic industry such as pharmaceuticals, the omission of 
new and exiting drugs can have important empirical implications.  For drugs, the 
evidence is that pricing for new drugs can be very different from that of older, more 
established drugs, indicating that an index that includes new drugs will likely show 
different price growth than one that does not (Berndt 2002).   
One way to better incorporate any price change for new drugs is to construct 
indexes over shorter spans of time and to cumulate, or chain, the resulting price indexes.  
                                                 
3 A geometric average of A and B is [AxB]
1/2, and numerically gives similar answers as the usual arithmetic 
mean (A+B)/2.   
  9For example, suppose we are measuring price change from 2003 to 2005 with annual 
price indexes.  One could construct two Fisher price indexes, one for price change from 
2003 to 2004 (I
F
2003,2004 ) and another for price change from 2004 to 2005 (I
F
2004,2005).  
One can then cumulate the growth in the two indexes to obtain a chained Fisher price 








2004,2005        ( 5 )  
 
The resulting index includes more spending on new drugs than the unchained version in 
(4).  While the only new drugs included in (4) are those introduced in 2003, the chained 
index includes drugs introduced in 2004 in the I
F
2004,2005 index.  Chained indexes thus 
provide a way of folding in new goods more quickly and so the index more closely tracks 
prices for the goods actually sold in the market.  One can construct a chained Laspeyres 
in a similar manner.         
  One paradigm that has been used to justify the superiority of the Fisher Ideal 
index over others is cost of living index (COLI) theory.  However, as discussed earlier, it 
is widely understood that the applicability of this theory in the health care setting is 
tenuous at best.  Fortunately, there are other criteria that one can use to compare the 
relative merits of these formulas.  In his “axiomatic approach,” Diewert (1992) considers 
about 20 properties that one would like to see in a price index.  For example, one 
property is a time-reversal test which requires that if the prices and quantities in the two 
periods being compared are interchanged the resulting price index is the reciprocal of the 
original price index.  Diewert showed that the Fisher index formula met this and other 
criteria better than other available formulas.       
 
Empirical results 
An important contribution of the empirical literature was to demonstrate that the 
choice of formula and chaining method matters.  The Fisher formula takes into account 
any changes in the relative importance of drugs over time, whereas the Laspeyres formula 
does not.  Chaining indexes brings new goods into the index more rapidly.    
The differences in these indexes can be positive or negative.  For example, in their 
study of drugs sold by four companies making up about 25% of the market, Berndt, 
  10Griliches and Rosett (1993) found that price growth in chained indexes was slower than 
that in fixed-based indexes.  But, in their study of antidepressant drugs, Berndt, Cockburn 
and Griliches (1996) found the opposite—chained Laspeyres tended to show faster price 
growth than the unchained counterparts.  Which way it goes depends on how fast prices 
for new goods grow relative to established goods, and how the composition of drugs in 
the market is changing over time.   
We illustrate these points using our data.  For our comparison, we used the 
preferred price per day for price, and did the calculations for both the NDC and GPI 
definitions of the product.        
Using the NDC definition, the chained indexes grow at CAGRs that are about .4 
percentage points slower than their unchained counterparts (about 10 percent of the 
unchained growth rate).  This says that folding in new goods into the index more quickly 
yields indexes that grow slower and suggests that, in our sample, prices of new drugs 
grow slower than those of older drugs.  With respect to choice of formula, the Laspeyres 
and Fisher indexes grow at very similar rates, whether the indexes are chained or not, 
under the NDC definition.   
[TABLE 3] 
A similar comparison using the GPI definition looks very different.  First, the 
chained price indexes show faster (not slower) price growth than the unchained ones.  
This reflects the fact that prices for new molecules grow faster than those of older 
molecules that include generics:  as molecules lose patent protection, the diffusion of the 
less expensive generics pushes down the price of the molecule.  Hence, folding in new 
molecules faster—as the chained indexes do—yields an index that includes molecules 
with faster price growth and so the chained index grows faster.  As before, the chained 
versions of the Laspeyres and Fisher are very similar.   
The unchained indexes show an interesting pattern.  They track prices for goods 
sold in 2003:1.  The unchained Laspeyres—the dotted line in chart 2—grows until mid-
2004 and then exhibits a declining trend through the last quarter in our data.  This contour 
is driven entirely by the influx of generics into the market over this period.  The pattern 
we see in the price index is mirrored in the number of generic prescriptions as a share of 
total:  the rise in prices in the earlier period is associated with a decline in the generic 
share and the subsequent decline in the price index coincides with sustained increases in 
  11the generic share.  By 2005:4, over 60% of prescriptions were for generic drugs, up from 
58% in 2003.  
[CHART 2] 
 
The unchained Fisher shows a similar pattern but it is less pronounced.  The 
patterns in the Fisher and Laspeyres indexes are similar because both indexes include the 
same molecules (both exclude entry and exit).  But, the Fisher shows slightly faster price 
growth because molecules with the fastest price growth also gain market share over time 
and thus have a bigger weight in the Fisher index than in the Laspeyres.    
Summing up, chained and unchained indexes can show very different rates of 
price growth.  In our data, the differences are particularly large for drugs defined as 
molecules (GPI definition) where the growth rates differ by orders of magnitude.   
 
Implications for decompositions of spending growth     
Spending on prescription drugs grew 30.9% from 2003:1 to 2005:4, or at a 9.4% 
CAGR.  Because different price indexes yield different growth rates for measured price 
change, they also yield different growth rates for the implied growth of quantities, or 
“utilization.”  We illustrate this by decomposing the 9.4% CAGR into price and quantity 
components using the eight possible price indexes discussed above.  In each case, we 
deflate the growth in spending using the price index to obtain the implied growth in 
utilization:  growth in spending / growth in prices = growth in quantities.  So that for the 
chained Laspeyres index that uses the NDC definition (in the top left portion of the table), 
the calculation is:  (1.0938/1.0262)=1.0659.   
  The use of different price indexes does not materially change the qualitative 
conclusion that all of the indexes attribute most of the growth in spending to growth in 
utilization, not price:  Of the 9.4% growth in spending, growth in utilization contributes 6 
to 9 percentage points, depending on the index.  Indexes that use the GPI definition of 
product attribute more than those based on the NDC definition: the unchained indexes 
that use the GPI definition essentially attribute all of the growth in spending to increases 
in utilization because measured price growth is essentially flat.   
For national accounting purposes, however, the differences of an implied growth 
rate for quantity of 8% CAGR—the chained Fisher using the GPI definition—and 6% 
  12CAGR—the unchained Laspeyres using the NDC definition—are large and the implied 
trends will be very different.  After five years, the level of one index would be 7 times the 
level of the other if these rates were sustained.     
We close by noting that this type of decomposition is similar in many respects to 
the decompositions that health economists use to parse out the drivers of cost growth
4 but 
there are differences.  In those decompositions, they first decompose overall spending 
growth into spending on new drugs versus growth in spending on established drugs 
(drugs that were sold in both periods).  They separate spending on new drugs because that 
spending growth is qualitatively different.  For example, increases in spending that are 
due to spending on new, better, drugs have a different implication for patients than 
increases in spending that arise from higher prices for older drugs.  They then construct a 
price index for the established drugs (drugs sold in 2003:1 that were also sold in 2005:4).  
For this purpose, unchained indexes are the relevant ones to use.  They use this price 
index, just as we have, to estimate the growth in spending on established drugs and 
separate it into price and utilization components.  Although the price index literature 
argues that the Fisher formula is superior to the Laspeyres, empirically, the choice of 
formula does not make much of a difference in our sample:  the Fisher and Laspeyres 
price indexes are very similar and, so, the implied growth rates for quantity are also very 




4.  Measuring Quality Change   
Ideally, one would want a price index that would take into account changes in the 
quality of goods.  For example, while the average price of computers has stayed fairly 
constant over the last two decades, the performance (speed of processor, data storage 
capabilities, etc.) has greatly improved.  Price indexes that take these enhancements into 
account should, and do, show rapid declines, reflecting rapid improvements in quality.  
These indexes are typically constructed by relying on market prices as a gauge of the 
market’s valuation of quality differences across goods to measure the value of quality 
indirectly—as is done in price indexes—or more directly—as in a hedonic regression.     
                                                 
4 See Merlis 2000 for a review. 
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end of the day, many believe that the complicated features of medical care markets do not 
allow the interpretation of prices as a gauge of patients’ valuations of drugs and hence 
question the ability of methods like price indexes and hedonics to adequately capture the 
quality of goods.  As we show here, the rates of quality change implied by standard 
methods are quite low.  Assuming that the quality of goods is improving over time, price 
growth measured using these techniques should perhaps be viewed as an upper bound on 
true price change, where the “true price change” would account for increases in quality 
over time.  Indeed, this is the view taken in studies that aim to assess the biases in official 
statistics. (Lebow and Rudd 2003).     
 
4.1 Quality in Matched-Model Indexes 
  We begin by asking “what do standard price indexes assume about quality?”  The 
average quality of goods increases both when existing goods get better over time and 
when new, better, goods enter the market.  The price indexes described above can control 
for the first issue of quality change in existing goods if the market and data allow one to 
track identical goods over time.  Markets where goods are “custom”—housing, for 
example—present difficulties because the nature of the good makes it difficult to track 
identical products over time.  But, this is not the case for drugs, where the available data 
have sufficient detail on the products so that one can track products with identical 
physical attributes over time.  If there are unobserved attributes that change over time 
(e.g. perceived efficacy or experience with the drug), these indexes will count any price 
increases associated with these changes as increases in price, not quality.   
The indexes also involve an implicit adjustment for quality change when new 
goods are introduced.  It can be shown that these indexes value the quality differences 
across goods as the difference in market prices that prevailed at the point of entry 
(Aizcorbe 2006).  Specifically, standard price indexes implicitly compare prices of new 
and incumbent goods and attribute that gap in prices to the market’s valuation of the 
quality differences in the goods.  
One problem with this kind of implicit valuation is that, as mentioned earlier, it is 
not clear that a comparison of prices provides patients’ valuations of the benefits of new 
drugs over established ones.  Another unsettling feature of this quality valuation is that it 
  14is applied only at the period of introduction.   Because the diffusion of new drugs is slow, 
the market share for the new drug is relatively small in the period it enters the market and 
grows over time.  If so, including the new drug in an index as soon as possible may imply 
a smaller quality estimate than bringing it in later.  Griliches and Cockburn (1995) 
discuss this issue in the context of new generics and show that different ways of handling 
diffusion can generate very different price indexes.  This remains an unresolved issue.   
 
4.2 Hedonic Price Indexes  
Hedonic regression techniques provide an explicit way to control for quality 
change when constructing price indexes.
5  A hedonic regression relates variation in 
prices, both across goods and over time, to differences in the goods’ attributes: bigger 
houses sell for more, higher resolution printers are more expensive, etc.  To the extent 
that these attributes are related to price, a hedonic regression can be used to capture these 
relationships and to construct price indexes that control for changes in these attributes or, 
changes in “quality.”   
The Regression 
Hedonic studies for drugs have typically applied the regression on pooled data 
and used time dummies to form a “dummy variable” (DV) price index.  As argued in 
Schultze and Mackie (2000) and Pakes (2003), this method constrains parameters to be 
fixed over time whereas the underlying parameters may well change over time.  
However, in cases where the available data do not allow estimation in each period, 
pooling the data and using the DV index is the only option.  This was, indeed, the case 
for hedonic studies of specific drugs, where the focus on narrowly defined medications 
did not typically yield sufficient observations to run cross-sectional regressions.   
We, thus, focus on the pooled specification and the DV price index.  The pooled 
hedonic regression explains the prices of each product that is sold at time t (Pi,t , i = 1 … 
 Ν ) as a function of the quantities of its characteristics (Ck,i,t, k = 1, …K) and time dummy 
variables (Di,t  , t = 1, …T).  The regression is usually specified in semi-logarithmic form:    
          
  ln Pi,t  =  Σk βkC k,i,t  + Σt δtDi,t + εi,t      (6) 
 
                                                 
5 See Berndt (1996) and Triplett (2006) for a full discussion of hedonic techniques 
  15where        Di,t     = 1 if a price for product m is observed at time t, and 
       = 0 otherwise,  
and βk, δt, and εi,t are econometric estimates.  Each product has K characteristics that can 
influence its value, and, in general, the quantity of each characteristic in a product can 
change over time.  The characteristics typically are numeric values (such as number of 
milligrams of active ingredient), but they can also be dummy variables that designate the 
presence or absence of an attribute of the good in a particular product (such as whether 
the drug is the extended release version).   
  There are a number of econometric issues in implementing hedonic regressions, 
including heteroskedasticity, unobserved characteristics, choice of functional form and 
imprecise estimates owing to collinearity (Berndt 1996).  The omitted variable issue was 
revisited by Bajari and Benkard (2005) and Pakes and Erickson (2009).  Bajari and 
Benkard argued that the existence of these unobservable characteristics pose problems for 
hedonic techniques that are made evident in the low explanatory power one typically 
obtains in these regressions.  Their work and that in Pakes and Erickson (2009) develop 
new methods that account for these unobserved characteristics and shows that accounting 
for them not only improves the explanatory power of the regression but also the 
inferences that one draws from them. 
On the interpretation of hedonic coefficients, Pakes (2003) argues that the hedonic 
regression should be interpreted as a reduced form, where the coefficients can reflect 
changes in both demand- and supply-side factors.  For drugs, demand-side factors include 
factors that increase the prevalence of some conditions and, hence, the demand for 
medications to treat them or new knowledge about the efficacy of drugs; supply factors 
can include the rising cost of research and development, or variation in marketing 
expenditures.  Under Pakes’ interpretation, there is no reason to expect coefficients 
associated with “good” outcomes to have positive signs. 
The Σk βkC k,i,t terms control for differences in products’ qualities, the regression 
delegates all other influences on prices to the time dummies and the (assumed normally 
distributed) residuals.  The time dummy coefficients, δt, capture the average value of the 
other influences for each time period, and are estimates of the aggregate constant-quality 
price level (rather than price relative) for the good at time t.  
Empirical results 
  16To date, there are only five studies that have used hedonic techniques to construct 
price indexes for drugs:  Suslow (ulcers), Berndt, Cockburn and Griliches (depression), 
Cockburn and Annis (arthritis), and Lucarelli and Nicholson (colorectal cancer).  All of 
these studies show that price indexes that control for differences in attributes across drugs 
and over time show substantially slower price growth than average prices.  
The kind of drug attributes that they used included features such as the efficacy of 
the drug (like healing or survival rates), ease of administration (number of daily doses 
needed for treatment), as well as the unwanted presence of side effects and interactions 
with other medications.  An advantage of this regression approach over matched-model 
price indexes is that it can accommodate attributes that change over time, something that 
matched-model indexes cannot.  For example, Cockburn and Anis (1998) include 
variables to reflect new information on old drugs from clinical trials—that is, what is 
known about drugs changes over time and that can be incorporated in the hedonic 
regression.  Similarly, Berndt et al. (2001) include an indicator for experience with the 
drug (cumulative sales), another variable that changes over time.  
Empirically, hedonic techniques applied to drugs have failed to find an 
overwhelming connection between the attributes and price. This result has also been 
reported in demand studies where the coefficient on price tends to be insignificant 
(Cockburn and Anis 1998 and Lucarelli and Nicholson 2009).  Some have noted that this 
might be a reflection that patients and doctors are not very sensitive to price.  Surveys 
cited in Suslow (1992) suggest that patients ranked affordability fourth in importance in 
the list of factors they look for in anti-ulcer medications, behind “Be safe,” “Make you 
feel better quickly,” and “Be convenient to take.”  Similarly, though doctors do include 
price in the list of factors they consider when prescribing drugs, it is not the most 
important thing.  This is consistent with the observation that prices can be fairly non-
responsive to relatively large changes in markets, including drugs coming off patent and 
the subsequent entry of generics.  
 
Dummy Variable Index 
The DV measure of price change (in logs) is the difference between the estimated 
time dummy coefficients for time 0 and time 1.
  When there is no entry and exit—i.e., all 
N goods were sold in both periods—the (logged) price index may be written:   
  17 
ln I
DV  =  δ1 - δ0       
 
 =   Σi ( ln Pi,1 - Σk βkC k,i,1)  / N1  
   




where the N's denote the total number of products and we ignore the (mean zero) 
residuals.  Note, then, that the (logged) DV measure for price change from time 0 to time 
1 is the difference of two (logged) geometric means: the mean of quality-adjusted prices 
for products that exist at time t, the first term, and that of products that exist at time 0, the 
second term.  
How does the DV index deal with new goods?  This issue was studied by Silver 
and Heravi (2002) and Aizcorbe, Corrado and Doms (2003).  Consider the introduction 
of a new good (call it “n”) at time 1.
  The DV price measure provides an explicit 
imputation for these missing prices.  To see this, augment (7) to include the new good.  
After some tedious algebra, the DV estimate for price change from t=0 to t=1 can be 




1,0    =     
δ1 -  δ0  = ( N0 / N1 ) [ Σ i (ln Pi,1 – ln Pi,0)  /  N1 ]  
  +  ( 1 / N1 ) [( ln Pn,1   − Σk βkC n,k,1 ) −  Σ i ( ln Pi,0 − Σk βkC k,i,0)  / N0 ]   (8) 
 
Equation (8) shows that the DV measure may be written as a weighted average of 
a price measure for continuing goods (the first term) and one for the new good (the 
second term) where the weights implicitly used by the hedonic regression are the share of 
observations of each type.  For continuing goods, the DV measure uses a geomean price 
index.  For the new good, the hedonic regression imputes a price relative as the difference 
between the quality-adjusted price for the new product at time 1 ( lnPn,1 − ΣkβkC n,k,1 ) and 
  18the average quality-adjusted price for all observed products in the prior period ( Σ i ( ln Pi,0 
− Σk βkC k,i,0)  / N0 ).   
This is similar to the implicit valuation in price indexes discussed above in that 
both use the period of introduction to account for quality; the DV price index thus shares 
the problem that standard price indexes have in trying to measure quality change in the 
presence of diffusion.  It differs, however, in that the hedonic explicitly estimates quality 
differences based on the hedonic coefficients.  Empirically, the DV measure typically 
gives slower price growth than price indexes (See, for example, table 4.4 in Berndt 1996).  
Some think that this is because the hedonic is better at capturing changes in quality than 
standard price indexes (Triplett, 2006).  Others have noted that these differences in price 
growth might arise from the fact that the DV price indexes are unweighted (like 
geomeans) whereas price indexes typically use expenditure weights (Aizcorbe and Pho 
2005). 
In our data, a DV index shows slower price growth and faster quality growth than 
either the chained Fisher or Laspeyres indexes.  One way to calculate the quality change 
implied by price indexes is using the identity:  dln(average price) = ln(price index) + 
dln(quality change).  There are choices to make about what to use as the average price 
and those choices could yield different measures for implied quality.  For a geomean 
price index, for example, if one measures the change in the average price as the change in 
geometric means of the logged price levels for prices of all goods sold in each period, 
then, the implied change in quality has a clean interpretation as the difference between 
the (logged) price of the new goods and the average (logged) price of all goods sold that 
period (Aizcorbe 2006).  For other index formulas, the implied quality term does not have 
a tidy interpretation.  Nonetheless, as a first cut, we do the calculations using differences 
in a geomean of the (logged) price levels to get a rough gauge of how much quality 
growth is implied by the different indexes.   
To obtain a DV price index, we estimate a hedonic regression that uses fixed 
effects to control for quality differences across drugs and relegates all other influences to 
the time dummies—we cannot do more than this because we do not observe the typical 
attributes used in hedonic regressions, like efficacy.  However, the drug-specific fixed 
effects will control for any of those attributes that are fixed over the life of the drug.  The 
  19raw data are logged prices at the NDC level and the fixed effects for drugs’ 
characteristics are at the GPI level.   
The first three columns of table 5 show the usual result that the DV price index 
attributes more of the spending growth to quality than to price.  The DV price index is 
essentially flat, actually falling at about a 1/4 percent CAGR and the implied rate of 
quality growth is 3%.  The quality growth implied by the Laspeyres and Fisher indexes is 
about one-half the growth of quality implied by the DV index:  about 1-1/2 % CAGR.    
These differences are not necessarily related to the fact that the DV index is based 
on a hedonic regression while the others are based on standard price index methods.  The 
last column of the table shows growth rates for a price index generated using an 
unweighted geometric mean formula.  The growth in that index is very similar to that of 
the DV index, perhaps because their functional forms are so similar—both are 
unweighted indexes.  However, the similarity only holds when the geomean index is 
chained, thereby including new goods quickly.   
[TABLE 5] 
 
A final point about these estimates of quality growth is that they seem small when 
compared with estimates for other goods.  For example, standard price indexes for Intel’s 
microprocessors implied quality growth of over 20 percent per quarter over the 1990s 
(Aizcorbe 2006).  Similarly, Bils and Klenow (2001) estimate that average quality of 
over 60 categories of durable goods grew 3-3/4 percent per year over the 1980-96 period.   
Compared with these rates of quality growth, the estimates for quality growth for 
drugs seem small and suggest that the methods discussed above do not adequately 
measure the value of new pharmaceutical innovations.  This probably reflects, in part, the 
inability of prices to provide a good gauge of patients’ valuations.  To the extent that the 
average quality of drugs improves over time, price indexes generated using standard 
methods are perhaps best viewed as upper bounds to an unobserved price index that takes 
these quality improvements into account.   
Measuring quality directly 
  Health economists view the output of medical services as the incremental 
improvements to health status that result from treatment.  Cost effectiveness studies try to 
measure this directly by comparing the incremental cost of transitioning from new to 
  20current treatments against the incremental benefits in terms of health outcomes or 
effectiveness with a cost-effectiveness ratio:
6 
 
CE ratio  =  [ costnew – costcurrent ]  /  [ effectnew – effectcurrent ]     (7) 
 
A seminal paper by Cutler, McClellan, Newhouse and Remler (1998) provided a cost of 
living interpretation to this notion of cost effectiveness by tying it back to utility analysis.  
For heart attacks, several different types of treatments are given at the same time (e.g. 
surgery and drugs) so their model compares the entire cost of treating the condition with 
the attendant outcomes.   
A close cousin of cost-effectiveness analysis is called “cost utility analysis,” 
where the cost-effectiveness ratios are expressed in terms of cost per quality-adjusted life 
year (QALY), an outcome measure that incorporates the value people place on different 
outcomes (Drummond et al. 1997).   
Similar cost-effectiveness calculations have been done to assess the quality of 
new drug treatments
7.  These calculations have been done using different data sources.  
For example, for colorectal cancer drugs, Lucarelli and Nicholson (2009) use industry 
data to estimate the incremental cost of new chemotherapy regimens (the numerator) and 
data from clinical trials to estimate the increase in life expectancy from the treatment, 
while Howard et al. (forthcoming) used retrospective survey data at the patient level to 
calculate the cost of chemotherapy and to estimate survival curves for calculating the 
incremental benefits in terms of increased longevity.   
  This would seem to be a promising method particularly when drugs are the only 
treatment (e.g. chemotherapy for certain cancers).  When drugs and other treatments are 
substitutes, however, new drugs can involve cost offsets, such as when a new drug makes 
the utilization of other treatments are no longer necessary, that should figure into this 
calculation.  Similarly, when drugs and other treatments are complements, it will be 
difficult to parse out the marginal improvements to health from drugs as opposed to other 
treatments.   
                                                 
6 see Garber (2000) for a review of this literature 
7 see Neumann et al. (2000) and Crown, Ling, and Berndt (2002) for a summary of the various methods 
that have been used to study the effectiveness of drugs 
  21  Although these direct methods are likely to have any number of methodological 
issues, they do provide a way to assess the value of drug improvements in a more 
transparent way than index methods.    
   
6. Price Indexes in Cross-Country Comparisons 
  Price indexes have also been used to compare drug prices in different countries.  
There, the question is “Are drugs more expensive in the U.S. than in other countries?” 
rather than “Are drugs more expensive today than they were yesterday?”  For 
pharmaceuticals, there are both informal comparisons based on individual drugs (U.S. 
General Accounting Office 1994) as well as more formal calculations that apply price 
indexes or regression techniques to more comprehensive data (Danzon and Chao 2000, 
for example).  Because the questions are very similar, many of the issues that arise in the 
context of the temporal price indexes discussed above also arise in the cross-country 
context.   
  Prices and utilization patterns for drugs vary greatly across countries so that cross-
country comparisons can give very different results depending on which drugs are 
included and how much weight each drug is given.  Perhaps the most vexing problem is 
that drugs sold in one country are often not sold in others so that the comparisons are 
necessarily incomplete.  For example, using a comprehensive dataset for seven countries, 
Danzon and Chao (2000) found that less than one-third of the molecules sold in seven 
countries are present in all seven markets.  Moreover, when making comparisons across 
pairs of countries, they found that over 40% of total retail pharmacy sales in their dataset 
could not be included.  This is the analog to the “new goods” problem in the temporal 
context and makes it very difficult to boil down differences in drug prices across 
countries into one summary statistic.     
For drugs common to the countries, comparisons based on price indexes are 
sensitive to choice of index formula.  The larger problem around the choice of formula is 
that, unlike in the temporal context, different formulas answer different questions:  a 
Laspeyres formula that uses the US as the base country tells you how much the US 
market basket of drugs would cost if one had to pay the other country’s prices.  The 
Paasche index tells you how much the other country would have to pay to buy their 
market basket at US prices.  The Fisher index—that gives an average of these two—has 
  22not been viewed as particularly informative in cross-country comparisons of drug prices.  
Moreover, the Laspeyres and Paasche indexes do not have the usual bounding 
interpretation because, as in the temporal context, the COLI theory does not apply here. 
  There is a fairly large literature devoted to indexes that may be used to do cross-
country comparisons or, more broadly, spatial comparisons.  Indexes have been used 
compare prices across regions of the US at a point in time (Kokoski 1991 and Aten 
2008), across countries at a point in time (Kravis, I.B., A. Heston and R. Summers 1982), 
and across both space and time (Hill 2003).  The studies use both index number 
approaches (Diewert 1999) and regression-based approaches (Summers 1973).    
 
7.  Summary  
  
  Existing work in this area has gone a long way toward improving our 
understanding of price indexes and the kinds of questions that they can and cannot 
address.  The lessons from this literature are numerous. 
  First, much has been learned about the relative merits of different aggregation 
schemes.  Indexes that more-closely track the composition of products sold in the market 
are better than those that do not:  chained indexes are better than unchained ones and the 
Fisher formula is better than the Laspeyres.       
  Second, different ways of dealing with the entry of generic drugs can yield very 
different price indexes.  Price indexes based on a GPI definition grow much slower than 
those based on the NDC definition.  The GPI indexes are viewed as the better way to 
define the product, with the caveat that perhaps patients do not always view branded and 
generic versions of drugs as perfect substitutes.  More work is needed to pin this down 
further.   
  Third, perhaps the most daunting problem is that existing methods do not provide 
an adequate way to deal with improvements provided by new drugs.  At the end of the 
day, many believe that the complicated features of medical care markets do not allow the 
interpretation of prices as a gauge of patients’ valuations of drugs and, hence, question 
the ability of methods like price indexes and hedonics to adequately capture the quality of 
goods.  What we’re left with is an interpretation of these indexes as upper bounds to true 
price change:  Assuming that the quality of drugs is improving over time, price indexes 
  23that do not adequately account for these better outcomes are overstating the price per 
quality unit to patients.  More work is needed to find alternative methods that allow one 
to infer the benefit to patients of new drugs.  Merging what is known about price indexes 
with cost effectiveness methods would seem to be a promising avenue of research.   
Finally, the problem of accounting for quality change is part of a broader issue.  
Namely, there are difficulties in tying these indexes to consumer welfare or , more 
specifically, to the improved outcomes from medications.  Without a COLI or similar 
paradigm, it is difficult to interpret changes in measured price growth as good or bad.  
Structural demand estimation that allows one to estimate utilities—like Lucarelli and 
Nicholson (2009)—is a promising line of research that could fill this gap.           
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Table 2.  Growth in Chained Price Indexes, 2003:1-2005:4: Definition of Quantity 
(compound annual growth rates)       
   NDC     GPI 
   Laspeyres  Fisher     Laspeyres  Fisher 
Days of Treatment  2.62%  2.60%    1.18% 1.20% 
          
Package 3.78%  3.49%    2.40%  2.14% 
          
Prescription 4.51%  4.42%    3.16%  3.11% 




































  30Table 3.  Effect of Chaining Price Indexes     
(compound annual growth rates)       
                   NDC                  GPI 
   Laspeyres  Fisher     Laspeyres  Fisher 
Chained 2.62%  2.60%    1.18%  1.20% 
          
Unchained 3.01%  2.96%    0.06%  0.53% 
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Table 4. Alternate Decompositions of Growth in Spending 
(compound annual growth rates)    
                   NDC               GPI    
   Laspeyres  Fisher  Laspeyres  Fisher 
Growth in Spending  9.38%  9.38%  9.38%  9.38% 
  
 Chained 
   Price 2.62%  2.60%  1.18%  1.20% 
   Quantity 6.59%  6.61%  8.11%  8.08% 
       
 Unchained 
   Price 3.01%  2.96%  0.06%  0.53% 
   Quantity 6.18%  6.24%  9.32%  8.80% 
Note: All prices are defined as price per day of treatment    
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Table 5.  Alternate Decompositions of Growth in Average Prices 
(compound annual growth rates)     
   Hedonic  Price Indexes 
   DV  Geomean  Laspeyres  Fisher 
        
Average Price  2.81%  2.81%  2.81%  2.81% 
Price Index  -0.25%  -0.18%  1.18%  1.20% 
Implied Quality  3.06%  2.99%  1.63%  1.61% 
Note: All prices are defined as price per day of treatment; all indexes are chained 
from 2003:1 to 2005:4 
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